The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:38
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [41] Long-acting HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) in South Africa: cost-effective at what cost?
    Jin, E. Y.
    Ahmed, A. R.
    Bekker, L. -G.
    Ciaranello, A.
    Flanagan, C. F.
    Freedberg, K. A.
    Orrell, C.
    Reddy, K. P.
    Wallace, M.
    Neilan, A. M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [42] Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis
    Beckham, S. Wilson
    Sanchez, Travis
    Fowler, Rebecca
    Zlotorzynska, Maria
    Rai, Mona
    Sullivan, Patrick
    Vannappagari, Vani
    Sarkar, Supriya
    Glick, Jennifer L.
    Rinehart, Alex R.
    Rawlings, Keith
    Bridges, John F. P.
    AIDS PATIENT CARE AND STDS, 2023, 37 (10) : 495 - 503
  • [43] Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
    Jeffrey T. Parsons
    H. Jonathon Rendina
    Thomas H. F. Whitfield
    Christian Grov
    AIDS and Behavior, 2016, 20 : 1390 - 1399
  • [44] Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
    Lorraine T. Dean
    Zachary Predmore
    Alexandra Skinner
    Siena Napoleon
    Philip A. Chan
    Julia Raifman
    AIDS and Behavior, 2023, 27 : 2606 - 2616
  • [45] Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
    Dean, Lorraine T. T.
    Predmore, Zachary
    Skinner, Alexandra
    Napoleon, Siena
    Chan, Philip A. A.
    Raifman, Julia
    AIDS AND BEHAVIOR, 2023, 27 (08) : 2606 - 2616
  • [46] Knowledge and attitudes of HIV pre-exposure prophylaxis among nurses in South Africa
    Bailey, Veronique C.
    Kleinhans, Atholl V.
    Mokgatle, Mathilda M.
    Vc, Bailey
    Av, Kleinhans
    AFRICAN JOURNAL OF PRIMARY HEALTH CARE & FAMILY MEDICINE, 2023, 15 (01)
  • [47] Willingness to Use Long-Acting Injectable Pre-Exposure Prophylaxis among Adolescent Girls and Young Women in Kampala, Uganda
    Lunkuse, Jane Frances
    Lwanga, Charles
    Wamono, Felix
    Muturi-Kioi, Vincent
    Price, Matt
    Mayanja, Yunia
    AIDS AND BEHAVIOR, 2025, : 1458 - 1469
  • [48] Preference for long-acting injectable pre-exposure prophylaxis among transgender women clients of the Tangerine Clinic in Bangkok, Thailand
    Himma, L.
    Siri, S.
    Janamnuaysook, R.
    Aimyoug, N.
    Munsawaengsub, C.
    Kongkapan, J.
    Rueannak, J.
    Srimanus, P.
    Avery, M.
    Mills, S.
    Ramautarsing, R.
    Phanuphak, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 31 - 32
  • [49] The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
    Walensky, Rochelle P.
    Park, Ji-Eun
    Wood, Robin
    Freedberg, Kenneth A.
    Scott, Callie A.
    Bekker, Linda-Gail
    Losina, Elena
    Mayer, Kenneth H.
    Seage, George R., III
    Paltiel, A. David
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (10) : 1504 - 1513
  • [50] Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment
    Dlamini, Wendy W.
    Mirembe, Brenda G.
    Krows, Meighan L.
    Peacock, Sue
    Kotze, Philip L.
    Selepe, Pearl
    Smit, Jenni
    Mandona, Nelly
    Louw, Cheryl
    Nuwagaba-Biribonwoha, Harriet
    Omollo, Victor O.
    Zwane, Zinhle
    Panchia, Ravindre
    Mwelase, Noluthando
    Senne, Melissa
    Naidoo, Logashvari
    Chihana, Rachel
    Delany-Moretlwe, Sinead
    Gill, Katherine
    Macdonald, Pippa
    van Heerden, Alastair
    Bosman, Shannon
    Peters, Remco P. H.
    du Preez, Philip
    Ward, Amy
    Celum, Connie
    Heffron, Renee
    Velloza, Jennifer
    INSIGHT Study Team
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2025, 28 (02)